[1] WHO.Fact sheet on Ebola virus disease[EB/OL].https://www.who.int/csr/resources/publications/ebola/coordination/en.
[2] WHO. Introduction to Ebola virus disease [EB/OL].https://www.who.int/csr/resources/publications/presentation.pdf?ua=1&ua=1.
[3] Coltart CE, Lindsey B, Ghinai I, et al.The ebola outbreak, 2013-2016: old lessons for new epidemics[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1721): 20160297.
[4] WHO. 2016 Ebola situation reports: archive [EB/OL]. http://www.who.int/csr/disease/ebola/situation-reports/archive/en.
[5] WHO. Ebola virus diseases [EB/OL].https://www.who.int/health-topics/ebola/#tab=overview.
[6] Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease): Transmission [EB/OL].https://www.cdc.gov/vhf/ebola/transmission/index.html.
[7] Harbourt DE, Johnston SC, Pettitt J, et al.Detection of Ebola Virus RNA Through Aerosol Sampling of Animal Biosafety Level 4 Rooms Housing Challenged Nonhuman Primates[J]. J Infect Dis, 2017, 215(4): 554-558.
[8] Mekibib B, Ariën KK.Aerosol Transmission of Filoviruses[J]. Viruses, 2016, 8(5): 148.
[9] Olejnik J, Ryabchikova E, Corley RB, et al.Intracellular events and cell fate in filovirus infection[J]. Viruses, 2011, 3(12): 1501-1531.
[10] WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections[J]. N Engl J Med, 2014, 371(16): 1481-1495.
[11] Warren TK, Wells J, Panchal RG, et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430[J]. Nature, 2014, 508(7496): 402-405.
[12] Florescu DF, Keck MA.Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses[J]. Expert Rev Anti Infect Ther, 2014, 12(10): 1171-1178.
[13] Smither SJ, Eastaugh LS, Steward JA, et al.Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model[J]. Antiviral Res, 2014, 104(3): 153-155.
[14] Wu W, Liu S.The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection[J]. Curr Top Med Chem, 2017, 17(3):361-370.
[15] Qiu X, Wong G, Audet J, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp[J]. Nature, 2014, 514(7520): 47-53.
[16] 冯子健. 埃博拉出血热及其防控策略(视频)[J]. 新发传染病电子杂志, 2017, 2(1):59.
[17] WHO. Travel and transport risk assessment: Ebola [EB/OL].https://apps.who.int/iris/bitstream/handle/10665/132168/WHO_EVD_Guidance_TravelTransportRisk_14.1_eng.pdf?sequence=1.
[18] WHO. Ebola event management at points of entry [EB/OL].https://apps.who.int/iris/bitstream/handle/10665/131827/WHO_EVD_Guidance_PoE_14.1_eng.pdf?sequence=1.
[19] WHO. Ebola in the Democratic Republic of the Congo: health emergency update [EB/OL]. Available from: https://www.who.int/emergencies/diseases/ebola/drc-2019.
[20] Kennedy SB, Bolay F, Kieh M, et al.Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia[J]. N Engl J Med, 2017, 377(15): 1438-1447.
[21] Henao-Restrepo AM1, Longini IM2, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial[J]. Lancet, 2015, 386(9996): 857-866.
[22] Milligan ID, Gibani MM, Sewell R, et al.Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial[J]. JAMA, 2016, 315(15): 1610-1623.
[23] Bengtsson KL, Song H, Stertman L, et al.Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice[J]. Vaccine, 2016, 34(16): 1927-1935. |
